Salicylic acid

Description

This product is identified by the code 51945-4 and is associated with the effective date of June 19, 2024. The principal display panel includes multiple images that provide visual representation of the product. The images are in JPEG format and are referenced as Label1.jpg, Label2.jpg, and Label3.jpg. The product is presented in a dosage form suitable for professional use, with specific details available in the accompanying visual materials.

Uses and Indications

This drug is indicated for the removal of common and plantar warts. Common warts are characterized by a rough, "cauliflower-like" appearance on the surface, while plantar warts are specifically located on the bottom of the foot, presenting with tenderness and an interruption of the footprint pattern.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Healthcare professionals are advised to follow the outlined procedure for the application and removal of the tag patch.

The affected area should be washed and dried thoroughly prior to application. Once prepared, the tag patch should be applied directly to the affected area. After a duration of 24 hours, the tag patch must be removed. This procedure may be repeated every 24 hours for a maximum of 14 days for tag removal, or up to 12 weeks for tag treatment until the condition has resolved.

To facilitate the removal process, it is permissible to apply a hot compress to the tag for 5 minutes using warm water prior to patch application. This may enhance the effectiveness of the treatment.

Contraindications

Use is contraindicated in the following situations:

Application on irritated skin or any area that is infected or reddened is prohibited due to the potential for exacerbating the condition. Additionally, the product should not be applied to moles, birthmarks, warts with hair growing from them, or warts located on the face or mucous membranes, as these conditions may pose a risk of adverse reactions.

Warnings and Precautions

To avoid the risk of suffocation, it is imperative to keep this plastic bag away from infants and children. This bag should not be utilized in cribs, beds, carriages, or playpens, as it poses a significant hazard. It is essential to recognize that this bag is not a toy and should be treated with caution.

Patients are advised to discontinue use and consult their healthcare provider if they experience any adverse reactions. Specifically, this product should not be applied to irritated skin or any areas that are infected or exhibiting signs of redness. Additionally, it is contraindicated for use on moles, birthmarks, warts with hair growth, or warts located on the face or mucous membranes.

Side Effects

Patients should be aware of the potential risks associated with the use of this product. There are specific warnings regarding the danger of suffocation; therefore, it is crucial to keep the plastic bag away from babies and children. The bag should not be used in cribs, beds, carriages, or playpens, as it is not a toy.

Additionally, patients are advised to discontinue use of the product if it is applied to irritated skin or any area that is infected or reddened. This includes moles, birthmarks, warts with hair growing from them, and warts located on the face or mucous membranes. Adhering to these guidelines is essential to minimize the risk of adverse reactions.

Drug Interactions

No specific drug interactions have been identified for this medication. Additionally, there are no reported interactions with laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Skin Tag One Step Patches. Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be closely monitored when using this product due to safety concerns. The plastic bag poses a suffocation risk; therefore, it must be kept away from infants and children. It is imperative to avoid using this bag in cribs, beds, carriages, or playpens, as it is not a toy. Additionally, the product should be kept out of reach of children to prevent accidental harm.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

There is currently no information available regarding the use of Skin Tag One Step Patches during pregnancy. This includes a lack of data on safety concerns, dosage modifications, or any special precautions that should be taken when considering the use of this product in pregnant patients. Healthcare professionals are advised to exercise caution and consider the absence of data when discussing treatment options with women of childbearing potential.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or lactation considerations. Healthcare professionals should exercise caution and consider the potential risks and benefits when prescribing this medication to lactating mothers. The effects on breastfed infants have not been established.

Renal Impairment

There is no information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution and consider the lack of specific guidance when prescribing to patients with reduced kidney function.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted based on clinical judgment.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved and the individual patient's response. Common symptoms of overdose may include, but are not limited to, altered mental status, cardiovascular instability, and respiratory distress.

In the event of an overdose, immediate medical intervention is recommended. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs. The use of activated charcoal may be considered if the patient presents within a suitable timeframe and if the ingestion was recent.

Furthermore, it is crucial to consult local poison control centers or toxicology experts for guidance on specific management protocols and antidotes, if applicable. Continuous assessment and supportive measures should be prioritized until the patient stabilizes or further treatment is determined.

Documentation of the incident, including the substance involved, estimated dose, and time of exposure, is vital for ongoing management and potential reporting requirements.

Nonclinical Toxicology

No information is available regarding teratogenic or non-teratogenic effects. Additionally, there is no data provided concerning nonclinical toxicology, animal pharmacology, or toxicology.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion or misuse.

Patients should be instructed not to use the medication on irritated skin or on any area that is infected or reddened. Additionally, it is important to inform patients to avoid application on moles, birthmarks, warts with hair growing from them, and warts located on the face or mucous membranes. This guidance is crucial to ensure safe and effective use of the medication.

Storage and Handling

The product is supplied in a configuration that ensures optimal handling and storage. It should be stored at room temperature, specifically in a dry place to maintain its integrity. Additionally, it is essential to protect the product from light exposure to prevent degradation. To ensure safety, the product must be kept out of reach of children at all times.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Skin Tag One Step Patches, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)